-
Open Medical Records: Pros and Cons
Patients now have full access to their online medical records. What are the benefits and downsides?
by Jen Tota McGivney
-
Remote Care
After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs' value for cancer patients undergoing treatment.
by Jon Kelvey
-
Moving Away From the Maximum Tolerated Dose
The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate.
by Marcus A. Banks
-
The Individual Sphere of Influence
Can discussion of health inequities lead to actionable change?
by Marci A. Landsmann
-
A Treatment That Came Just in Time
Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
More Data on COVID-19 Vaccination and Cancer
Studies indicate that many people with cancer have an antibody response to the vaccines, but this response may be reduced or absent in certain patients.
by Anna Goshua
-
Putting the Patient in the Driver’s Seat
In her new book, Cancer Support Community executive chair Kim Thiboldeaux offers advice to patients on how to steer their way through a cancer diagnosis, treatment and beyond.
by Kevin McLaughlin
-
A Closer Look at Sarcopenia
Gastrointestinal oncologist and health services researcher Ryan Nipp discusses new research about how muscle quality correlates with cancer outcomes.
by Ashley P. Taylor
-
Genetic Testing Gaps
Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling.
by Kate Yandell
-
Rethinking Access to Disability Benefits
Advances in screening and treatment mean there are more cancer survivors than ever, but survivors who struggle to work can face difficulty getting disability payments.
by Jen Tota McGivney
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore